Cover Image
市場調查報告書

EpiCast Report:慢性淋巴性白血病的流行病學預測

EpiCast Report: Chronic Lymphocytic Leukemia - Epidemiology Forecast to 2023

出版商 GlobalData 商品編碼 301138
出版日期 內容資訊 英文 41 Pages
訂單完成後即時交付
價格
Back to Top
EpiCast Report:慢性淋巴性白血病的流行病學預測 EpiCast Report: Chronic Lymphocytic Leukemia - Epidemiology Forecast to 2023
出版日期: 2014年05月01日 內容資訊: 英文 41 Pages
簡介

所謂慢性淋巴性白血病(CLL),是白血球(淋巴球)癌症的一種,帶給特定的淋巴球(B細胞)--主要骨髓、血液內集積,對抗感染疾病的細胞--不良影響。CLL在西歐各國是一般白血病形態,年度平均發病率為每10萬人口有5.0件(不論年齡)。基本上是老年人發病的疾病,40歲以下的患者比例為10%以下。全球主要6個國家的發病數量,從2013年的37,795件,預計到2023年增加到45,683,其年複合成長率(CAGR)推算為2.09%。還有治療完畢的患病人數,從2013年的150,800人,到2023年增加到183,165(年複合成長率(CAGR)是2.15%)。

本報告提供全球主要6個國家(美國、法國、德國、義大利、西班牙、英國)的慢性淋巴性白血病(CLL)的發病情形和今後預測相關分析、疾病的特徵(風險要素和主要的共生病症等等)全球各國的趨勢、目前患病者的發病情形、今後10年的發病、患病數量的預測值等調查評估,並將其結果依為您概述為以下內容。

第1章 目錄

第2章 簡介

  • 概要
  • 近日出版的相關調查

第3章 流行病學

  • 疾病的背景
  • 風險要素和共生病症
  • 全世界的趨勢
    • 發病數量
    • 存活率:美國、歐洲5個國家的情況
  • 預測手法
    • 利用之資訊來源
    • 未利用之資訊來源
    • 預測的前提條件與手法:確診的發病數量
    • 預測的前提條件與手法:確診的患病人數(今後5年份)
    • 預測的前提條件與手法:診斷時的Rai分類
  • 慢性淋巴性白血病(CLL)的流行病學預測(今後11年份)
    • 確診的發病數量
    • 確診的發病數量(各年齡)
    • 確診的發病數量(性別)
    • 確診的發病數量(已調整年齡)
    • 確診的發病數量(診斷時的各Rai分類)
    • 確診的患病人數:今後5年的預測
  • 議論
    • 流行病學性的預測相關結論
    • 分析的限制
    • 分析的優勢

第4章 附錄

圖表一覽

目錄
Product Code: GDHCER060

Chronic lymphocytic leukemia (CLL), also known as chronic lymphoid leukemia, is a type of cancer of the white blood cells (lymphocytes). CLL affects a particular lymphocyte, the B cell, which accumulates mainly in the bone marrow and blood, and normally fights infection.

CLL is the most common form of leukemia in the western world, with an average annual incidence of 5.0 per 100,000 population in people of all ages. CLL is primarily a disease of the elderly population, with less than 10% of the cases below 40 years of age.

GlobalData epidemiologists forecast an increase in the diagnosed incident cases of CLL in the 6MM, from 37,795 diagnosed incident cases in 2013 to 45,683 diagnosed incident cases in 2023, with an annual growth rate (AGR) of 2.09% during the forecast period. The 5-year diagnosed prevalent cases of CLL in the 6MM increased from 150,800 diagnosed prevalent cases in 2013 to 183,165 diagnosed prevalent cases in 2023, with an AGR of 2.15% during the forecast period.

GlobalData's epidemiological forecast for the diagnosed incident and 5-year diagnosed prevalent cases of CLL in the 6MM is supported by age- and sex-specific data for incidence and 1- to 5-year relative survival data used for the 5-year diagnosed prevalent cases forecast are supported by country-specific, population-based studies that are nationally representative of the entire population in the respective markets. The diagnosed incident cases of CLL in each of the 6MM were further segmented by Rai stage at diagnosis to provide a more detailed analysis of the patient population, as Rai stage at diagnosis is an important factor for predicting the prognosis and treatment modalities for CLL at different stages.

Scope

  • The Chronic lymphocytic leukemia (CLL) EpiCast Report provides an overview of the risk factors, comorbidities, and the global and historical trends for CLL in the six major markets (6MM) (US, France, Germany, Italy, Spain, and UK). In addition, the report also includes a 10-year epidemiological forecast of the diagnosed incident cases of CLL segmented by age (beginning at 40 years and ending at 80 years and older) and sex. GlobalData epidemiologists also forecast the 5-year diagnosed prevalent cases of CLL in the 6MM. Additionally, the report provides CLL diagnosed incident cases segmented by Rai stage at diagnosis for the 6MM.
  • The CLL epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 6MM.

Reasons to buy

  • Develop business strategies by understanding the trends shaping and driving the global CLL market.
  • Quantify patient populations in the global CLL market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the sex and age groups that present the best opportunities for CLL therapeutics in each of the markets covered.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Upcoming Reports

3. Epidemiology

  • 3.1. Disease Background
  • 3.2. Risk Factors and Comorbidities
  • 3.3. Global Trends
    • 3.3.1. Incidence
    • 3.3.2. Survival from CLL - US and 5EU
  • 3.4. Forecast Methodology
    • 3.4.1. Sources Used
    • 3.4.2. Sources Not Used
    • 3.4.3. Forecast Assumptions and Methods, Diagnosed Incident Cases
    • 3.4.4. Forecast Assumptions and Methods, 5-Year Diagnosed Prevalent Cases
    • 3.4.5. Forecast Assumptions and Methods, Rai Stage at Diagnosis
  • 3.5. Epidemiological Forecast of CLL (2013-2023)
    • 3.5.1. Diagnosed Incident Cases of CLL
    • 3.5.2. Age-Specific Diagnosed Incident Cases of CLL
    • 3.5.3. Sex-Specific Diagnosed Incident Cases of CLL
    • 3.5.4. Age-Standardized Diagnosed Incidence of CLL
    • 3.5.5. Diagnosed Incident Cases of CLL by Rai Stage at Diagnosis
    • 3.5.6. 5-Year Diagnosed Prevalent Cases of CLL
  • 3.6. Discussion
    • 3.6.1. Epidemiological Forecast Insight
    • 3.6.2. Limitations of the Analysis
    • 3.6.3. Strengths of the Analysis

4. Appendix

  • 4.1. Bibliography
  • 4.2. About the Authors
    • 4.2.1. Epidemiologists
    • 4.2.2. Reviewers
    • 4.2.3. Global Director of Epidemiology and Health Policy
    • 4.2.4. Global Head of Healthcare
  • 4.3. About GlobalData
  • 4.4. About EpiCast
  • 4.5. Disclaimer

List of Tables

  • Table 1: CLL Clinical Stages at Diagnosis
  • Table 2: Risk Factors and Comorbidities for CLL
  • Table 3: Trends in the Age-Adjusted Incidence of CLL in the US, All Ages, 2003-2010
  • Table 4: Trends in the Age-Adjusted Incidence of CLL(Cases per 100,000 Population) in France, All Ages, 1980-2012
  • Table 5: Trends in the 5-Year Relative Survival (%) of CLL in the US and 5EU, Both Sexes, 1993-2009
  • Table 6: Sources of Epidemiological Data Used for the Forecast for CLL Incident and Prevalent Cases, and the Rai Stage at Diagnosis
  • Table 7: 6MM, Diagnosed Incident Cases of CLL, Both Sexes, Ages ≥40 Years, N, 2013-2023
  • Table 8: 6MM, Age-Specific Diagnosed Incident Cases of CLL, Both Sexes, N (Row %), 2013
  • Table 9: 6MM, Sex-Specific Diagnosed Incident Cases of CLL, Ages ≥40 Years, N (Row %), 2013
  • Table 10: 6MM, 5-Year Diagnosed Prevalent Cases of CLL, Both Sexes, Ages ≥40 Years, N, 2013-2023

List of Figures

  • Figure 1: 6MM, Diagnosed Incident Cases of CLL, Both Sexes, Ages ≥40 Years, N, 2013-2023
  • Figure 2: 6MM, Age-Specific Diagnosed Incident Cases of CLL, Both Sexes, N, 2013
  • Figure 3: 6MM, Sex-Specific Diagnosed Incident Cases of CLL, Ages ≥40 Years, N, 2013
  • Figure 4: 6MM, Age-Standardized Diagnosed Incidence of CLL (Cases per 100,000 Population), Ages ≥40 Years, by Sex, 2013
  • Figure 5: 6MM, Diagnosed Incident Cases of CLL by Rai Stage at Diagnosis, Ages ≥40 Years, N, 2013
  • Figure 6: 6MM, 5-Year Diagnosed Prevalent Cases of CLL, Both Sexes, Ages ≥40 Years, N, 2013-2023
Back to Top